SB 328437,CCR3拮抗剂
SB 328437,CCR3拮抗剂结构式
|
常用名 | SB 328437,CCR3拮抗剂 | 英文名 | SB 328437 |
|---|---|---|---|---|
| CAS号 | 247580-43-4 | 分子量 | 378.37800 | |
| 密度 | N/A | 沸点 | N/A | |
| 分子式 | C21H18N2O5 | 熔点 | N/A | |
| MSDS | N/A | 闪点 | N/A | |
| 符号 |
GHS07, GHS09 |
信号词 | Warning |
|
CCR3 antagonists: a survey of the patent literature.
Expert Opin. Ther. Pat. 19(8) , 1109-32, (2009) Since the mid-1990s, there has been significant effort invested in the discovery and clinical development of CC chemokine receptor-3 (CCR3) antagonists as potential therapeutics for airway disease.A patent literature review is presented of small molecule CCR3... |
|
|
Selective suppression of Th2-mediated airway eosinophil infiltration by low-molecular weight CCR3 antagonists.
Int. Immunol. 19(8) , 913-21, (2007) The effects of selective CC chemokine receptor (CCR)-3 antagonists on antigen-induced leukocyte accumulation in the lungs of mice adoptively transferred with in vitro-differentiated T(h)1 and T(h)2 were investigated. Inhalation of antigen by mice injected wit... |
|
|
CCR3 and choroidal neovascularization.
PLoS ONE 6 , e17106, (2011) Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of ce... |